Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YN 001

Next Previous
Drug Profile

YN 001

Alternative Names: YN-001

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Inno Medicine
  • Class Cardiovascular therapies; Vascular disorder therapies
  • Mechanism of Action CD44 antigen inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis
  • Phase I Cardiovascular disorders

Most Recent Events

  • 30 Sep 2025 Beijing Inno Medicine plans a phase I trial in healthy volunteers in Australia (IV, Infusion) in October 2025 (NCT07190885)
  • 29 Aug 2025 Efficacy data from a phase Ib/IIa trial in Atherosclerosis presented at the Annual Congress of the European Society of Cardiology together with World Congress of Cardiology (ESC-Card-WCC-2025)
  • 27 Apr 2025 Beijing Inno Medicine completes a phase I/II trial in Atherosclerosis in China (IV) (NCT06048588)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top